Advancing the science of veterinary therapeutics.

Active sites and binding pockets diverge between species. Many compounds that work in humans lose potency in canines or felines. We rapidly validate small molecule binding via in silico homology modeling and structural docking, then confirm activity in species-specific cell-based assays — resolving translatability before advancing to in vivo studies.

Cross-species pharmacokinetics is rarely linear. Bioavailability, half-life, and tissue distribution can differ by 2–5x or more, and naive dose translation routinely overshoots or undershoots the therapeutic window. We confirm appropriate dosing in target species populations via pharmacokinetic studies. Target exposure is calibrated from species-specific cell-based assays and, where available, inferred from human response data.

Disease presents differently in companion animals than in humans — endpoints, biomarkers, and trial design must be built for veterinary medicine. We are building an efficient clinical trial network managed with purpose-built software and supported by leading academic veterinary KOLs across oncology, immunology, and internal medicine, alongside FDA-CVM-experienced regulatory leads. Our approach uses computational methods — including digital twin modeling — to optimize trial design, and companion diagnostics to identify the patient populations most likely to benefit — improving outcomes while reducing trial size and cost.